[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cosmetique Active International\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":260},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,72,98,123,147,172,195,213,237],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100625988","evaluation-of-efficacy-and-tolerabilty-of-melab3-serum-in-combination-of-35-glycolic-acid-peeling-compared-to-35-glycolic-acid-peeling-alone-in-various-hyperpigmentation-conditions-100625988",false,"NCT07429786","Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peeling Compared to 35% Glycolic Acid Peeling Alone in Various Hyperpigmentation Conditions","Randomized Clinical Trial to Assess the Effectiveness and Tolerability of MELA B3 Serum in Combination With 35% Glycolic Acid Peel vs. 35% Glycolic Acid Peel for the Treatment of Various Hyperpigmentation Conditions (Melasma, Post-inflammatory Hyperpigmentation and Solar Lentigo) and Signs of Aging in a Population of Participants From the Autonomous City of Buenos Aires, Argentina.","Inclusion Criteria:\n\n1. Women and men\n2. From 30 to 70 years of age (inclusive)\n3. Good general health\n4. With any type of phototype\n5. Hyperpigmentation condition with average darkness \\> 3:\n\n   1. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2)\n   2. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face\n   3. Solar lentigo (SL) with a pigmentation score\\>5\n6. Willingness to protect oneself from the sun as much as possible for the duration of the study\n7. Willingness to avoid contraindicated products (irritants, other depigmenting agents)\n8. Signing of written informed consent\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding or with pregnancy plans.\n2. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier).\n3. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit.\n4. Active acne with 10 or more inflammatory lesions.\n5. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth.\n6. Participant using irritating products (require a washout period of at least 2 weeks).\n7. Use of medications that may induce melasma, such as antiepileptics (requires a washout period of 1 month).\n8. Use of other products with depigmenting activity (requires a washout period of 1 month).\n9. Other facial dermatoses or known photosensitivity, or a pre-existing or latent dermatologic health condition and\u002For disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that, in the judgment of the investigator, are considered inappropriate for participation or may interfere with study results.\n10. Topical treatments applied to the face (requires a 2-week washout period).\n11. Scheduled facial procedures during the course of the study.\n12. Participants undergoing phototherapy (requires a 1-month washout period).\n13. Known hypersensitivity to study products.\n14. History of laser resurfacing procedures, intense pulsed light, facial radiofrequency, deep peeling, facial mesotherapy with tranexamic acid, botulinum toxin or dermal filler injections, or cosmetic procedures on the face within 6 months prior to the start of the study.\n15. Facial treatment with microdermabrasion within 6 weeks prior to study entry.\n16. Persons with visible tanning, scars, moles, excessive hair or other dermal conditions on the face that, in the judgment of the investigator, may influence the results of the study.\n17. History of skin cancer, immunosuppression or immunodeficiency disorders (including HIV infection or AIDS), or current use of immunosuppressive drugs.\n18. Uncontrolled disease such as asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism. Persons with multiple health conditions may be excluded, even if controlled by diet or medication.\n19. Participation in another clinical trial within one week prior to entering this study.",true,"ALL","30 Years","70 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Randomized clinical trial to assess the effectiveness and tolerability of Mela B3 serum in combination with 35% glycolic acid peel vs. 35% glycolic acid peel for the treatment of various hyperpigmentation conditions (melasma, post-inflammatory hyperpigmentation and solar lentigo) and signs of aging in a population of participants from the Autonomous City of Buenos Aires, Argentina.",[28,29,30,31],"Hyperpigmentation","Melasma","Solar Lentigo","Peeling","NOT_YET_RECRUITING","2026-02-17",{"date":35,"type":36},"2026-02-24","ACTUAL",{"date":38,"type":22},"2026-03-04",{"date":40,"type":22},"2026-06",{"name":42,"class":43},"Cosmetique Active International","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100618698","study-of-the-photoprotection-and-prevention-of-actinic-damage-with-anthelios-fluide-100-ka-uvmune-400-in-patients-with-multiple-actinic-keratoses-100618698","NCT07335003","Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses","Prospective Randomized Controlled Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses","Inclusion Criteria:\n\n1. Adult outpatients ≥ 60y old with at least 11 clinically typical actinic keratosis lesions, including at least one on the face;\n2. Patient having understood and signed a written informed Consent Form to participate in the study indicating the potential participant's willingness to undergo the study procedures and complete the study.\n\nExclusion Criteria:\n\n1. Atypical actinic keratosis lesions including suspected squamous cell carcinoma and basal cell carcinoma (could be present at screening and treated but cannot be present at 1st visit);\n2. History of \\>2 squamous cell carcinomas;\n3. Known history of immunodepression whatever its cause in the past year;\n4. Participants who cannot undergo skin biopsies, with a history of scarring problems or who have developed adverse effects from the use of local anesthesia will also be excluded.\n5. Participant using interferon or interferon inducers, immunomodulators, cytotoxic or immunosuppressive drugs, corticosteroids, retinoids, other keratolytics or have received investigational drug within 4 weeks before enrolment\n6. Participant having active, localized or systemic infection other than the AK lesions\n7. Participant having any dermatological affection within the treated and adjacent area according to the Investigator judgement\n8. Participant having a present or past skin condition that according to Investigator judgment, deems inappropriate for study participation\n9. Participant having other significant medical conditions that according to Investigator Judgment, deems inappropriate for study participation\n10. Participant having a known hypersensitivity, allergy or contraindication to any ingredients contained within the cosmetic products,\n11. Participant taking part or intending to take part in another study for 30 days prior to D1 visit, and 30 days following last study visit. that according to Investigator judgment, deems inappropriate or may interfere for study participation\n12. Participant using light-based devices such as but not limited to PUVA (Psoralen Ultraviolet A therapy), IPL (Intense Pulsed Light), laser, LED (Light Emitting Diode) devices or tanning beds, within 4 weeks before enrolment.\n13. Participant having applied any topical product on the investigational areas the day of enrolment visit,\n14. Participant under legal guardianship or incapacitation.\n15. Participant being psychologically incapable of signing informed Consent Form and unable to comply with the protocol requirements according to investigator judgment.","60 Years",{"count":21,"type":22},[25],"Participants will be invited to take part in a research study as they have been diagnosed with multiple actinic keratosis lesions (AK). AK usually present as small, rough, dry, scaly and\u002For crusty patches or papules of the skin that can be skin-coloured pink, red, tan or a combinationof colours and are often easier to feel than see at their earlier stages. AK are commonly diagnosed in adults, particularly in patients aged 45 years and older and are considered to be pre-cancerous lesions.\n\nThe research is aiming to investigate the protective effect of an investigational sunscreen known as Anthelios Fluide 100 KA+ UVMune 400, when used together with good sun protection habits (which include staying in the shade during the hours of 11 am and 3 pm, wearing sun-protective clothing, wearing a wide-brimmed hat) in participants with multiple Actinic keratoses's.\n\nEligible participants will be randomly assigned into 1 of 2 groups - an intervention or control group The study main objective is to evaluate tested sunscreen prevention on actinic keratosis lesions.",[56],"Actinic Keratosis (AK)",[58,59,60,61],"Prevention","Photoprotection","actinic keratosis","diagnosis","RECRUITING","2026-01-06",{"date":65,"type":36},"2026-01-12",{"date":67,"type":36},"2025-07-01",{"date":69,"type":22},"2029-03",{"name":42,"class":43},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":80,"minAge":81,"maxAge":19,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":71},"100611372","clinical-investigation-to-evaluate-the-efficacy-and-safety-of-epilady-prototype-device-followed-by-application-of-a-topical-formula-on-depigmentation-of-lentigo-spots-100611372","NCT07239726","CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS","CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS IN HEALTHY WOMEN PARTICIPANTS - STUDY UNDER DERMATOLOGICAL CONTROL","EPILADY","Inclusion Criteria:\n\n* Healthy female participants aged between 35 and 70 years old at the time of inclusion.\n* All Fitzpatrick skin phototypes (I to VI) are eligible; groups I-II and V-VI should include at least one participant per group.\n* Presence of at least two solar lentigo (dark spots) on each hand or forearm, with each spot measuring less than 100 mm x 100 mm as assessed by the investigator.\n* Participant has read, understood, and accepted the constraints of the clinical investigation.\n* Participant has provided written informed consent to participate in the clinical investigation.\n* Participant is able to understand the language used in the investigational site and comprehend the information provided.\n* Participants are cooperative and compliant, aware of the clinical investigation requirements and willing to adhere to the full duration of participation and follow-up visits, in line with the CIP requirements.\n* Women of childbearing potential must commit to using an effective contraceptive method throughout the clinical investigation period and for at least three months prior to the inclusion visit, with no changes during that time.\n\nExclusion Criteria:\n\n* • Participants with dry or sensitive skin, as assessed by the investigator.\n\n  * Participants who have used cosmetic products with exfoliating or astringent claims on the hands within 4 weeks prior to the baseline visit.\n  * Participants who have used any home-use or professional low-level laser therapy (LLLT) or have participated in clinical studies involving LLLT within the 6 months preceding the baseline visit\n  * History of light-induced seizures or chronic migraine disorders.\n  * History of photosensitivity or photoallergic reactions.\n  * Presence of underlying dermatological conditions on the hands\u002Fforearms that, in the opinion of the investigator, could interfere with the clinical investigation assessments.\n  * A family history of melanoma in first- or second-degree relatives (parents or grandparents).\n  * Presence of excessive moles, non-lentigo pigmented lesions, tattoos, scars, or irritated skin in the test area that could affect the validity of the investigation.\n  * History of surgical procedures involving the areas designated for treatment.\n  * Participants who have been exposed to or plan to be exposed to sunbathing or artificial UV sources (e.g., mountain sports, phototherapy, tanning salons) within 1 month before the clinical investigation start or during the clinical investigation period.\n  * Use of suntan or self-tanning products within the 2 weeks preceding the baseline visit.\n  * Change in cosmetic habits (e.g., moisturizers, skincare, shower gels) during the 2 weeks prior to baseline.\n  * Use of any medications, topical treatments, skincare products, or aesthetic procedures listed in the CIP without observing the required wash-out periods, or unwillingness\u002Finability to comply with those restrictions during the clinical investigation.\n  * Participant who cannot be contacted by telephone in case of emergency\n  * Participant in an exclusion period or participating in another biomedical research clinical investigation (self-reported)\n  * Intellectual\u002Fmental inability to follow clinical investigation instructions (if suspected) or incapacitation.\n  * Participants working for the contract research organization (CIDP) in charge of this clinical investigation.","FEMALE","35 Years",{"count":83,"type":22},44,[25],"To assess the efficacy of the Epilady investigational device, used with and without a topical depigmenting formula, in reducing the appearance of lentigo spots on the hands and forearms of healthy female participants over an 84-day period",[30],[88,89],"solar lentigo,","Laser treatment","2025-11-16",{"date":92,"type":36},"2025-11-20",{"date":94,"type":22},"2026-01-07",{"date":96,"type":22},"2026-05-08",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":71},"100569672","evaluation-of-efficacy-of-anthelios-sunscreen-on-face-versus-usual-routine-on-signs-of-aging-100569672","NCT06697288","Evaluation of Efficacy of Anthelios Sunscreen on Face Versus Usual Routine on Signs of Aging","Evaluation of the Efficacy of the UVMune 400 Fluid Sunscreen on the Face Versus Usual Photoprotection Routine on Visible and Measurable Signs of Aging","Inclusion Criteria:\n\n* Subjects with signs of photo aging (Global score of at least 14)\n* All skin types\n\nExclusion Criteria:\n\n* Any history of significant dermatological\u002Fophthalmological diseases or conditions or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes,) which could, in the opinion of the Investigator, preclude topical application of the investigational products and\u002For interfere with the evaluation of the test site\n* Pregnant or breastfeeding women\n* Subject with known allergy to cosmetic products or to any ingredient of the sunscreen product",{"count":106,"type":22},260,[25],"This experimental, randomized study aims at evaluating the preventative effect of a Sun Protection Factor (SPF) 50+ sunscreen (Anthelios UVMUNE 400 Fluid SPF 50+) with high Ultraviolet A (UVA) protection on clinical signs of skin aging.",[110],"Aging",[112,113,114],"skin aging","Anthelios UVMUNE 400 Oil Control Fluid SPF 50+","preventive effect","2024-11-18",{"date":117,"type":36},"2024-11-20",{"date":119,"type":36},"2024-04-03",{"date":121,"type":22},"2025-08",{"name":42,"class":43},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":16,"sex":130,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100561485","benefits-of-a-cosmetic-anti-hair-loss-in-males-with-hair-loss-100561485","NCT06590779","Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss","Evaluation of the Benefits of a Cosmetic Anti-hair Loss Lotion Applied in Combination With Finasteride in Male Subjects With Hair Loss: Investigator-blinded, Randomized, Multi-center Study Performed Under Dermatological Control","Inclusion Criteria:\n\n* Male subject aged 18-41 years old with skin type I to IV according to the Fitzpatrick scale;\n* Affected by androgenetic alopecia with hair loss evaluated grade IIA to IV the modified Norwood-Hamilton scale;\n* Subject with chestnut brown, dark or black hair;\n* Subject with hair length ≥ 3 cm on the vertex and agreeing to keep this minimum length for the duration of the study;\n* Subject agreeing to have a shaved zone of 1.5 cm² on scalp area;\n* Subject accepting not to dye, bleach his hair or to do a permanent wave during the whole study duration;\n* Subject accepting to use condoms if her partner is pregnant.\n\nExclusion Criteria:\n\n* Female subject;\n* Subject presenting a life-threatening endocrine disease, neoplasia or other serious diseases;\n* Subjects suffering from chemo-induced alopecia (poisoning, medicines), or resulting from a chronic disease (genetic, endocrine, immunological, deficiencies), seasonal hair loss;\n* Subject having any other concomitant dermatological affection of the scalp (psoriasis, seborrheic dermatitis, eczema, other alopecia than androgenetic);\n* Subject suffering from a recurrent, acute, non-stabilized or evolving disease judged by the investigator able to interfere with the study needs and hair growth;\n* Subject having had surgical intervention for capillary correction (e.g., hair transplant) or intending to have recourse to this surgery during the entire study period;\n* Subject presenting a hypersensitivity to any of the components of the finasteride medication or to any 5-alpha-reductase inhibitor;\n* Subject that has applied or taken prior to the start of the study (screening) interfering drugs or products\n* Subject taking any other medical treatment (topic or per os) likely to interfere on hair growth or hair loss within 6 months prior to the screening visit;\n* Subject following a long period (\\>30 days) treatment of anti-inflammatory within 4 months prior to the start of the study (screening visit);\n* Subject taking topic cosmetic treatment or per os nutritional supplement likely to interfere on hair growth or hair loss during the last 3 months prior to the screening visit;\n* Subject having a topical or oral route treatment of the scalp (anti-seborrheic, anti-dandruff, daily friction) within 2 weeks prior to the screening visit;\n* Subject who has been exposed within one month prior to the screening visit in an intense or excessive manner to sun (natural or artificial) or during the study;\n* Subject having a wig or hair extension;\n* Protected subject as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or subject to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person subject to a legal protection measure or unable to express his\u002Fher consent;\n* Subject unable to communicate or cooperate with the Investigator due to poor mental development, language problems or impaired cerebral function;\n* Subject currently participating in another clinical study or being in an exclusion period of another clinical study;","MALE","18 Years","41 Years",{"count":134,"type":22},140,[25],"Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. AGA is a polygenetic condition with varying severity, age of onset, and scalp location of hair loss. In men, hair loss typically involves the temporal and vertex region while sparing the occipital region: the characteristic \"horseshoe\" pattern. Incidence and prevalence of AGA depend on age and race.\n\nVichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia. The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone.\n\nThe primary objective of this investigator-blinded, randomized multi-center study is to quantitatively evaluate, using the phototrichogram method, the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia.",[138],"Androgenetic Alopecia","2024-09-10",{"date":141,"type":36},"2024-09-19",{"date":143,"type":22},"2024-11-02",{"date":145,"type":22},"2026-05-02",{"name":42,"class":43},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":71},"100535564","efficacy-and-tolerability-of-tested-formula-after-3-months-of-treatment-of-facial-hyperpigmentation-of-3-origins-100535564","NCT06253468","Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins","Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo","Inclusion Criteria:\n\n* all phototypes\n* only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo\n* female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study\n* patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study\n\nExclusion Criteria:\n\n* female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study\n* male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)\n* patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.\n* severe melasma, dermal melasma\n* patient with facial pigmentary disorders other than those described in inclusion criteria\n* patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0\u002FBaseline visit\n* patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0\u002FBaseline visit;\n* patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0\u002FBaseline visit",{"count":155,"type":22},72,[25],"The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.",[28],[160,161,162,163],"facial hyperpigmentation","melasma","acne induced PIHP","solar lentigo","2024-08-03",{"date":166,"type":36},"2024-08-06",{"date":168,"type":36},"2024-06-14",{"date":170,"type":22},"2025-03",{"name":42,"class":43},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":16,"sex":80,"minAge":131,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":71},"100555756","anti-pigmenting-effect-of-a-routine-of-facial-products-in-subjects-with-melasma-100555756","NCT06516224","Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma","Evaluation of the Efficacy of the Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma","Inclusion Criteria:\n\n* 18-65 years\n* Phototype II-V\n* 50% with sensitive skin (declarative);\n* Subjects should be affected by well defined symmetrical (on both sides of the face) epidermal melasma (clinically diagnosed under Wood's light examination) lasting since more than a year\n\nExclusion Criteria:\n\n* Subjects under topical or systemic retinoids;\n* Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion;\n* Subjects under systemic immunosuppressants and considered immune compromised\n* Subjects under active treatment of melasma (including topicals or procedures) within the last 3 months\n* Pregnant women and\u002For breastfeeding women\n* Subjects with a recent change in contraception (since less than 6 months);\n* Subjects known allergy to any component of tested product;\n* Subjects not presenting with the conditions needed to comply with the protocol;\n* Subjects without any other dermatological conditions on the face\n* Subject under menopause phase with hormonal replace therapy\n* Subjects in the initial phase, change or discontinuation of hormonal treatment (estroprogesterone, cyproteron acetate, androgenic...) in the last 3 months;\n* Subjects currently using any medication, which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.\n* Subjects unable to give their informed consent.","65 Years",{"count":181,"type":22},150,[25],"This 6 month, comparative study assesses the benefit of a dermocosmetic regimen (Serum B3 + B3 retinol night cream) for 6 months compared to hydroquinone 4% (the gold standard in hyperpigmentation) followed by the dermocosmetic regimen for 3 months or the Kligman Trio for 3 months followed by the dermocosmetic regimen for 3 months in adult women with melasma on the face.",[29],[161,186],"hyperpigmentation","2024-07-18",{"date":189,"type":36},"2024-07-23",{"date":191,"type":22},"2024-07-15",{"date":193,"type":22},"2025-01-31",{"name":42,"class":43},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":157,"conditions":203,"keywords":204,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":71},"100536720","efficacy-and-tolerability-of-the-tested-formula-after-3-months-in-treatment-of-facial-hyperpigmentation-of-3-origins-100536720","NCT06268496","Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins",{"count":201,"type":22},60,[25],[28],[160,161,162,163],"2024-07-10",{"date":207,"type":36},"2024-07-12",{"date":209,"type":36},"2024-03-14",{"date":211,"type":22},"2024-07",{"name":42,"class":43},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":71},"100551733","evaluation-of-effaclar-duom-on-acne-lesions-in-subjects-with-mild-to-moderate-acne-on-face-and-trunk-100551733","NCT06463925","Evaluation of Effaclar Duo+M on Acne Lesions in Subjects With Mild to Moderate Acne on Face and Trunk","Evaluation of Effaclar Duo+M on Inflammatory and Non-Inflammatory Lesions in Subjects With Mild to Moderate Acne on Face and Trunk (Back and Chest)","Inclusion Criteria:\n\n* phototype I to VI\n* mild to moderate acne on the face and trunk\n\nExclusion Criteria:\n\n* cutaneous pathology on the studied zone other than acne\n* topical or systemic treatment during the previous weeks liable to interfere with the assessment of the acceptability and efficacy of the studied products",{"count":221,"type":22},65,[25],"This single-center, open, non-randomized study aims the efficacy evaluation of Effaclar Duo+M and Effaclar+M Purifying foaming gel on total acne lesion count, pigmented lesions and scars for 6 months in subjects with mild to moderate facial and truncal acne.",[225],"Acne",[227,228,229],"facial and truncal acne","Effaclar Duo+M","acne lesions",{"date":231,"type":36},"2024-06-18",{"date":233,"type":36},"2023-12-07",{"date":235,"type":22},"2024-09",{"name":42,"class":43},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":16,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":71},"100537168","effect-of-lipikar-urea-30-before-actinic-keratoses-treatment-100537168","NCT06274320","Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment","Investigation of the Effect of a 2 Weeks Lipikar Urea 30% Application Preceding a Planned Topical 5-FU 4% Actinic Keratoses Treatment on Efficacy of 5-FU 4%","Inclusion Criteria:\n\n* diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp\n* planned treatment of actinic keratoses of the scalp with Tolak®\n* Olsen grade I or II\n\nExclusion Criteria:\n\n* known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30%\n* treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)\n* suspected invasive squamous cell cancer in the treatment area\n* chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil",{"count":245,"type":22},100,[25],"This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion\u002Fexclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.",[249],"Actinic Keratoses",[251,252,253],"actinic keratoses","Lipikar Urea 30%","Olsen grade",{"date":231,"type":36},{"date":256,"type":36},"2024-04-05",{"date":258,"type":22},"2025-06",{"name":42,"class":43},""]